Mitogen-activated protein kinase 2 regulates physiological and pathological bone turnover

Journal of Bone and Mineral Research

Volumn 28, Issue 4, 2013, Pages 936-947

  Braun, Tobias ^a   Lepper, Johannes ^a   Ruiz Heiland, Gisela ^a   Hofstetter, Willy ^b   Siegrist, Mark ^b   Lezuo, Patrick ^c   Gaestel, Matthias ^d   Rumpler, Monika ^e   Thaler, Roman ^e   Klaushofer, Klaus ^e   Distler, Jörg H W ^a   Schett, Georg ^a   Zwerina, Jochen ^a,e  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

^c Association for the Study of Osteosynthesis Research Institute   (Switzerland)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e HANUSCH HOSPITAL   (Austria)

Author keywords

bone resorption; mitogen activated protein kinases; MK2; osteoporosis

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CALCITONIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; OSTEOPROTEGERIN; PROTEIN C FOS; ESTROGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE CELL; BONE MASS; BONE TURNOVER; CELL DIFFERENTIATION; CONTROLLED STUDY; CORTICAL THICKNESS (BONE); DNA BINDING; FEMALE; GENE EXPRESSION; HOMEOSTASIS; MALE; MICRO-COMPUTED TOMOGRAPHY; MONOCYTE; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OVARIECTOMY; POSTMENOPAUSE; PRIMARY CELL CULTURE; PROMOTER REGION; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE ACTIVATION; TRABECULAR BONE; ANIMAL; BONE DEVELOPMENT; BONE REMODELING; C57BL MOUSE; CELL COUNT; DEFICIENCY; METABOLISM; ORGAN SIZE; PATHOLOGY;

ANIMALS; BONE REMODELING; BONE RESORPTION; CELL COUNT; ESTROGENS; FEMALE; MALE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASE 1; ORGAN SIZE; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; OSTEOPROTEGERIN; OVARIECTOMY;

EID: 84875293053     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1816     Document Type: Article

References (36)

1. Sanchez-Riera L, Wilson N, Kamalaraj N, Nolla JM, Kok C, Li Y, Macara M, Norman R, Chen JS, Smith EU, Sambrook PN, Hernandez CS, Woolf A, March L., Osteoporosis and fragility fractures. Best Pract Res Clin Rheumatol. 2010; 24: 793-810.
2. Takayanagi H., Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nate Rev Immunol. 2007; 7: 292-304.
3. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM., OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999; 397: 315-23.
4. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL., TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest. 2000; 106: 1481-8.
5. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL., IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest. 2005; 115: 282-90.
6. Li YP, Stashenko P., Proinflammatory cytokines tumor necrosis factor-alpha and IL-6, but not IL-1, down-regulate the osteocalcin gene promoter. J Immunol. 1992; 148: 788-94.
7. van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C., Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum. 2006; 54: 3104-12.
8. Ghozlani I, Ghazi M, Nouijai A, Mounach A, Rezqi A, Achemlal L, Bezza A, El Maghraoui A., Prevalence and risk factors of osteoporosis and vertebral fractures in patients with ankylosing spondylitis. Bone. 2009; 44: 772-6.
9. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM., Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999; 402: 304-9.
10. Johnson GL, Lapadat R., Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002; 298: 1911-2.
11. Gaestel M., MAPKAP kinases-MKs-two's company, three's a crowd. Nat Rev Mol Cell Biol. 2006; 7: 120-30.
12. Ronkina N, Kotlyarov A, Dittrich-Breiholz O, Kracht M, Hitti E, Milarski K, Askew R, Marusic S, Lin LL, Gaestel M, Telliez JB., The mitogen-activated protein kinase (MAPK)-activated protein kinases MK2 and MK3 cooperate in stimulation of tumor necrosis factor biosynthesis and stabilization of p38 MAPK. Mol Cell Biol. 2007; 27: 170-81.
13. Kotlyarov A, Neininger A, Schubert C, Eckert R, Birchmeier C, Volk HD, Gaestel M., MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat Cell Biol. 1999; 1: 94-7.
14. Hegen M, Gaestel M, Nickerson-Nutter CL, Lin LL, Telliez JB., MAPKAP kinase 2-deficient mice are resistant to collagen-induced arthritis. J Immunol. 2006; 177: 1913-7.
15. Gorska MM, Liang Q, Stafford SJ, Goplen N, Dharajiya N, Guo L, Sur S, Gaestel M, Alam R., MK2 controls the level of negative feedback in the NF-kappaB pathway and is essential for vascular permeability and airway inflammation. J Exp Med. 2007; 204: 1637-52.
16. Culbert AA, Skaper SD, Howlett DR, Evans NA, Facci L, Soden PE, Seymour ZM, Guillot F, Gaestel M, Richardson JC., MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity. Relevance to neuroinflammation in a transgenic mouse model of Alzheimer disease. J Biol Chem. 2006; 281: 23658-67.
17. Zaiss MM, Sarter K, Hess A, Engelke K, Bohm C, Nimmerjahn F, Voll R, Schett G, David JP., Increased bone density and resistance to ovariectomy-induced bone loss in FoxP3-transgenic mice based on impaired osteoclast differentiation. Arthritis Rheum. 2010; 62: 2328-38.
18. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR., Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2: 595-610.
19. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Müller R., Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 2010; 25: 1468-86.
20. Anusaksathien O, Laplace C, Li X, Ren Y, Peng L, Goldring SR, Galson DL., Tissue-specific and ubiquitous promoters direct the expression of alternatively spliced transcripts from the calcitonin receptor gene. J Biol Chem. 2001; 276: 22663-74.
21. Reddy SV, Hundley JE, Windle JJ, Alcantara O, Linn R, Leach RJ, Boldt DH, Roodman GD., Characterization of the mouse tartrate-resistant acid phosphatase (TRAP) gene promoter. J Bone Miner Res. 1995; 10: 601-6.
22. Lee SE, Woo KM, Kim SY, Kim HM, Kwack K, Lee ZH, Kim HH., The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone. 2002; 30: 71-7.
23. Nakamura H, Hirata A, Tsuji T, Yamamoto T., Role of osteoclast extracellular signal-regulated kinase (ERK) in cell survival and maintenance of cell polarity. J Bone Miner Res. 2003; 18: 1198-205.
24. He Y, Staser K, Rhodes SD, Liu Y, Wu X, Park SJ, Yuan J, Yang X, Li X, Jiang L, Chen S, Yang FC., Erk1 positively regulates osteoclast differentiation and bone resorptive activity. PloS One. 2011; 6: e24780.
25. Lai CF, Chaudhary L, Fausto A, Halstead LR, Ory DS, Avioli LV, Cheng SL., Erk is essential for growth, differentiation, integrin expression, and cell function in human osteoblastic cells. J Biol Chem. 2001; 276: 14443-50.
26. David JP, Sabapathy K, Hoffmann O, Idarraga MH, Wagner EF., JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J Cell Sci. 2002; 115: 4317-25.
27. Matsuguchi T, Chiba N, Bandow K, Kakimoto K, Masuda A, Ohnishi T., JNK activity is essential for Atf4 expression and late-stage osteoblast differentiation. J Bone Miner Res. 2009; 24: 398-410.
28. Raingeaud J, Whitmarsh AJ, Barrett T, Derijard B, Davis RJ., MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol Cell Biol. 1996; 16: 1247-55.
29. Korb A, Tohidast-Akrad M, Cetin E, Axmann R, Smolen J, Schett G., Differential tissue expression and activation of p38 MAPK alpha, beta, gamma, and delta isoforms in rheumatoid arthritis. Arthritis Rheum. 2006; 54: 2745-56.
30. Cano E, Doza YN, Ben-Levy R, Cohen P, Mahadevan LC., Identification of anisomycin-activated kinases p45 and p55 in murine cells as MAPKAP kinase-2. Oncogene. 1996; 12: 805-12.
31. Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M., Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J Biol Chem. 2000; 275: 31155-61.
32. Zwerina J, Hayer S, Redlich K, Bobacz K, Kollias G, Smolen JS, Schett G., Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction. Arthritis Rheum. 2006; 54: 463-72.
33. Bohm C, Hayer S, Kilian A, Zaiss MM, Finger S, Hess A, Engelke K, Kollias G, Kronke G, Zwerina J, Schett G, David JP., The alpha-isoform of p38 MAPK specifically regulates arthritic bone loss. J Immunol. 2009; 183: 5938-47.
34. Greenblatt MB, Shim JH, Zou W, Sitara D, Schweitzer M, Hu D, Lotinun S, Sano Y, Baron R, Park JM, Arthur S, Xie M, Schneider MD, Zhai B, Gygi S, Davis R, Glimcher LH., The p38 MAPK pathway is essential for skeletogenesis and bone homeostasis in mice. J Clin Invest. 2010; 120: 2457-73.
35. Schottelius AJ, Zugel U, Docke WD, Zollner TM, Rose L, Mengel A, Buchmann B, Becker A, Grutz G, Naundorf S, Friedrich A, Gaestel M, Asadullah K., The role of mitogen-activated protein kinase-activated protein kinase 2 in the p38/TNF-alpha pathway of systemic and cutaneous inflammation. J Invest Dermatol. 2010; 130: 481-91.
36. Mourey RJ, Burnette BL, Brustkern SJ, Daniels JS, Hirsch JL, Hood WF, Meyers MJ, Mnich SJ, Pierce BS, Saabye MJ, Schindler JF, South SA, Webb EG, Zhang J, Anderson DR., A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. J Pharmacol Exp Ther. 2010; 333: 797-807.